Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

NGM Bio Presents Updated Preliminary Findings From Ongoing Phase 1b Dose Escalation Trial Of NGM120 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Cancer At AACR Special Conference: Pancreatic Cancer

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 +

NGM